Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation
This study has been terminated.
Sponsor:
Sanofi-Aventis
Information provided by:
Sanofi-Aventis
ClinicalTrials.gov Identifier:
NCT00790101
First received: November 11, 2008
Last updated: January 10, 2011
Last verified: January 2011
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date ICMJE | November 11, 2008 | ||||
Last Updated Date | January 10, 2011 | ||||
Start Date ICMJE | June 2004 | ||||
Primary Completion Date | |||||
Current Primary Outcome Measures ICMJE |
Compare the effects of risedronate and raloxifene on lumbar spine (LS) bone mineral density (BMD) in osteopenic women previously treated with HRT, who discontinued HRT at least 3 months prior to the study but no greater than 18 mos [ Designated as safety issue: No ] | ||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | Complete list of historical versions of study NCT00790101 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures ICMJE |
Compare the effects of risedronate, raloxifene, and placebo on BMD of the hip [ Designated as safety issue: No ] | ||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||
Current Other Outcome Measures ICMJE | |||||
Original Other Outcome Measures ICMJE | |||||
Descriptive Information | |||||
Brief Title ICMJE | Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation | ||||
Official Title ICMJE | An 18-Month, Multicenter, Parallel-Group Study to Determine The Relative Efficacy of Risedronate Versus Raloxifene in Subjects Who Have Discontinued Hormone Replacement Therapy (HRT) for Early Intervention in Osteoporosis | ||||
Brief Summary | This is a multi-center, randomized, double-blind, double-dummy study designed to compare the effects of risedronate, raloxifene, and placebo on BMD, bone turnover markers, and other markers of anabolic activity in postmenopausal women who previously received HRT. |
||||
Detailed Description | |||||
Study Type ICMJE | Interventional | ||||
Study Phase | Phase 4 | ||||
Study Design ICMJE | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Prevention |
||||
Condition ICMJE | Osteoporosis, Postmenopausal | ||||
Intervention ICMJE |
|
||||
Study Arm (s) |
|
||||
Publications * | |||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Terminated | ||||
Enrollment ICMJE | 6 | ||||
Completion Date | October 2004 | ||||
Primary Completion Date | |||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial |
||||
Gender | Female | ||||
Ages | up to 65 Years | ||||
Accepts Healthy Volunteers | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Location Countries ICMJE | United States | ||||
Administrative Information | |||||
NCT Number ICMJE | NCT00790101 | ||||
Other Study ID Numbers ICMJE | HMR4003B_4033 | ||||
Has Data Monitoring Committee | |||||
Responsible Party | Medical Affairs Study Director, Sanofi-Aventis | ||||
Study Sponsor ICMJE | Sanofi-Aventis | ||||
Collaborators ICMJE | |||||
Investigators ICMJE |
|
||||
Information Provided By | Sanofi-Aventis | ||||
Verification Date | January 2011 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |